Angiotensin Receptor II type 1 and the activation of Myosin Light-Chain Kinase and Protein Kinase C-βII. Mini Review.

Gerry A. Smith, Department of Biochemistry University of Cambridge, Tennis Court Rd. Cambridge CB2 1QW UK
gas1000@cam.ac.uk

Frank-Starling; angiotensin receptor; muscle contraction; myosin light chain kinase; Protein Kinase C-βII; myosin light chain phosphatase; β-arrestin; myosin bound MgATP → MgADP-phosphomyosin; myosin LC affinity for Ca^{2+}.

Summary.

The involvement of the angiotensin II type 1 receptor in the Frank-Starling Law of the Heart, where the various activations are very limited, allows simple analysis of the kinase systems involved and thence extrapolation of the mechanism to that of angiotensin control of activation of cardiac and skeletal muscle contraction. The involvement of phosphorylation of the myosin light chain in the control of contraction is accepted but not fully understood. The involvement of troponin-I phosphorylation is also indicated but of unknown mechanism. There is no known signal for activation of myosin light chain kinase or Protein Kinase C-βII other than Ca^{2+}/calmodulin but the former is constitutively active and thus has to be under control of a regulated inhibitor, the latter kinase may also be the same. Ca^{2+}/calmodulin is not activated in Frank-Starling, i.e. there are no diastolic or systolic [Ca^{2+}] changes. I suggest here that that the regulated inhibition is by myosin light chain phosphatase and/or β-arrestin. Angiotensin activation is by translocation of the β-arrestin from the sarcoplasm to the PM thus reducing its kinase inhibition action in the sarcoplasm, this reduced inhibition has been wrongly attributed to a mythical downstream agonist property of β-arrestin.

Frank-Starling Law of the Heart.

It will seem strange to initiate this study with the following full consideration of the Frank-Starling law of the Heart (FSLH), increase in contraction with increased ventricular filling, i.e. increase in contraction on increase in myofibril length in diastole. The involvement of secondary factors on myocyte length increase activation is very limited allowing correct attribution of functions. For example Van der Velden et al suggest that sarcomere length dependence of calcium sensitivity and the effects of phosphorylation by protein kinase A (PKA) of troponin-I (cTn-I) and C-protein are independent¹, and Steinberg² reports that protein kinase C (PKC) activation via Ca^{2+}/calmodulin would reduce contractile strength and no changes in lipid based activators are reported on
stretch. Solaro\textsuperscript{3} et al report that PKA phosphorylation has a negative effect on Ca\textsuperscript{2+} sensitivity but they get mixed up with the weak binding of Mg\textsuperscript{2+} to the troponins which has absolutely no effect on the activation of the cross-bridge. Solaro\textsuperscript{4} also reports minimal effects of mimics of PKC phosphorylation of cTnI. Neither of the common PKA or PKC take part in FSLH.

The chemistry of contraction

My recent study\textsuperscript{5} of the mechanism of FSLH led me to reconsider the Ca\textsuperscript{2+} cooperativity of contraction of normal heart\textsuperscript{6} and its inhibition\textsuperscript{7} by Mg\textsuperscript{2+}. The conclusion of this was that the cross-bridge is a doubly Ca\textsuperscript{2+} dependent ATPase that is restricted by myosin binding protein-C (MyBP-C) to use of CaATP as apparent substrate, i.e. the myosin-ATP bound Mg\textsuperscript{2+} has to be exchanged with Ca\textsuperscript{2+} for the cross-bridge to function in normal muscle. The consequential rate limiting step is release of phosphate which indicates phosphate is initially reversibly transferred to the myosin light chain\textsuperscript{8,9},

\[
\text{MgATP-myosin} \rightleftharpoons \text{MgADP-phosphomyosin}
\]

followed by the exchange of Mg\textsuperscript{2+} for Ca\textsuperscript{2+},

\[
\text{Ca}^{2+} + \text{MgADP-phosphomyosin} \rightleftharpoons \text{CaADP-phosphomyosin} + \text{Mg}^{2+}
\]

Followed by completion of the lever arm and back to the resting state,

\[
\text{CaADP-phosphomyosin} \rightleftharpoons \text{CaADP-myosin} + \text{Pi}
\]
\[
\text{MgATP} + \text{CaADP-myosin} \rightleftharpoons \text{MgATP-myosin} + \text{CaADP}
\]

It may be that the Pi release is dependent on the MgATP binding.

Both of the exchange of Ca\textsuperscript{2+} for Mg\textsuperscript{2+} and the cross-bridge initiation by Ca\textsuperscript{2+} binding to troponin-C (Tn-C)\textsuperscript{10,11} makes the Ca\textsuperscript{2+} activation of the cross-bridge cooperative\textsuperscript{5} i.e. the Hill coefficient for Ca\textsuperscript{2+} activation is 2.

The limits to effectors in FSLH

With the length induced contraction increase there is no associated decrease in the Hill coefficient and the shift of sensitivity to lower [Ca\textsuperscript{2+}] is positive but relatively small\textsuperscript{5}. This is converse to the situation where the Ca\textsuperscript{2+} restricting function of MyBP-C breaks down, as occurs in hypertrophic cardiomyopathy\textsuperscript{6}, with mostly mutations of MyBP-C or its reversible deactivation/removal\textsuperscript{6,12,13}. As there is no change in the Ca\textsuperscript{2+} cooperativity, Hill coefficient, the length induced shift to lower [Ca\textsuperscript{2+}] activation is simply the result of raising the effective Ca\textsuperscript{2+} affinity of either the cTn-C or the MgADP-phosphomyosin\textsuperscript{5,6,8,9}. A recent study by Irving et al with structural sensitive probes\textsuperscript{14} indicates that it is not the thin filament cTn-C Ca\textsuperscript{2+} affinity but the MgADP-phosphomyosin affinity for Ca\textsuperscript{2+} increase that is key to length induced activation, in that changes in the myosin head region, myosin light chain 2 (MLC2), are responsible for the stretch induced amplification of maximal tension. They also report that minimal
Although kinase action on the troponins does change functional agreed phosphorylation there is essential to produce the By the use of knock in the level of adrenalin activation is constitutively active and must occur, vide infra uncatalyzed calmodulin binding protein of unknown function. When bound to calmodulin It is extremely likely that the phosphorylation targets of MLCK are much altered vide infra active PKC of diglyceride by phorbol ester where it could phosphorylate the cTn calmodulin modification chain kinase (MLCK) has been shown on length increase of the myoc possible swamped by MLCK2 phosphorylation increase with calmodulin, PKC-βII has been shown to bind to the thin filament on activation by phorbol ester where it could phosphorylate the cTn-I, however no evidence of diglyceride change has been shown on length increase of the myocyte. If PKC-βII is involved it most probably is in the sarcoplasm, is constitutively active for cTn-I and is hindered by the kinase inhibitor β-arrestin as is MLCK, vide infra.

It is extremely likely that the phosphorylation targets of MLCK are much altered when bound to calmodulin, as are those of PKC-βII, it is accompanied by a calmodulin binding protein of unknown function. Demonstration of direct, uncatalyzed by calmodulin, phosphorylation by MLCK is lacking but this kinase is constitutively active and must occur, vide infra. In FSLH there is no change in the level of adrenalin activation hence not Ca/Calmmodulin action.

By the use of knock-out mice the misnamed (personal interpretation) “multifunctional” transducer protein β-Arrestin20 has also been shown to be essential to produce the length induced tension increase and small shift towards the cTn-C Ca2+ sensitivity through the angiotensin II type 1 receptor (AT1R), but not via the G-protein phosphoinositide-Ca2+ second messenger system, i.e. there is no change in diastolic or systolic [Ca2+] involved15. Protein phosphorylation15 does though appear to be strongly involved as it is generally agreed that it is central to strength of contraction. In the case of MyBP-C and its functional insistence on Mg2+-Ca2+ exchange6 one might expect the observed change in contraction on its PKA induced phosphorylation23 but not in FSLH. Although kinase action on the troponins does also modulate contraction
strength\textsuperscript{15}, but again coupling with length induced changes has not been directly demonstrated and common PKA or PKC are not involved\textsuperscript{1,2,3,4}. Downstream β-Arrestin stimulated Ca\textsuperscript{2+}-independent phosphorylation has also been muted\textsuperscript{20} but again not shown (does not exist? See later).

The one key observation is that Losartan, a drug that blocks AT1R activation, is found to block the length induced enhancement of cardiac sensitivity\textsuperscript{20}. So on length increase it would seem the AT1R is activated by an unknown mechanism, reflected in the losartan action. In any striated muscle when AT1R is activated the next step in the sequence is phosphorylation of the activated AT1R tail by adrenergic receptor kinase (GRK), not PKA or C, followed by translocation of β-Arrestin from the cytoplasm to bind strongly to the phosphorylated AT1R\textsuperscript{20,24,25} at the plasma membrane (PM). This binding inhibits further phosphorylation of the AT1R. β-Arrestin is a kinase inhibitor!! This is from where its name originates with discovery in the optic system\textsuperscript{26,27}. Like a tiger no way does it change its spots with its location (see above “does not exist” and “misnamed as multifunctional”).

The effect of β-Arrestin translocation in muscle cells

Myosin light chain-2 (MYL2) and its phosphorylation\textsuperscript{21,22,27,28,29} are central to the control of muscle contraction strength. MLCK activity would fit very well with the structural changes reported in the myosin heads on stretch activation, see above\textsuperscript{14}. Generally in striated muscle MLCK is Ca\textsuperscript{2+} and calmodulin dependent but is also constitutively active, i.e. it has been found to have a variable fraction of its maximal activity in the absence of Ca\textsuperscript{2+} and calmodulin\textsuperscript{21,22,23}. The variability probably arises with the level of self-phosphorylation reported. MLCK possibly has different substrate sensitivities when bound to Ca/calmodulin or not and is associated in vivo with a calmodulin inhibitor of unknown function that possibly inhibits low level Ca\textsuperscript{2+}/Calmodulin activation thus preserving the suggested specificity of action. In the presence of Calmodulin it is specific for MYL2, and cTn-I has not been investigated. In the absence of AT1R activation MLCK is almost certainly partially inhibited by the kinase inhibitor β-arrestin that is normally present in the sarcoplasm, possibly binding the MYL2 bound MgATP $\rightleftharpoons$ MgADP-phosphomyosin\textsuperscript{2,6,8,9}. One can envisage a MYL2 phosphorylation level maintained by MLCK and light chain phosphatase\textsuperscript{30} (LCP) and also regulated by β-arrestin, a central point of control of contraction. Reduction of β-arrestin inhibition of MLCK occurs on translocation of the β-arrestin to strongly bind to the AT1R on the PM on angiotensin activation. In length induced contraction strength increase the essential phosphorylation of cardiac cTn-I on threonine 144 possibly also occurs this way, clearly not by normal PKA or PKC\textsuperscript{1,2,3,4}. This does not preclude direct PKA or PKC related changes in striated muscle when changes other than angiotensin activation occur such as adrenergic stimulation. This increase in phosphorylation of MYL2 by MLCK increases the affinity of the MgADP-
phosphomyosin for Ca\textsuperscript{2+} over that for Mg\textsuperscript{2+}, more Ca\textsuperscript{2+} chelating phosphate groups, shifting the sensitivity to lower [Ca\textsuperscript{2+}] and increasing contractile strength. This is supplemented by Tn-I phosphorylation at residue 144, lowering its inhibitory role\textsuperscript{15}. The myosin bound MgATP $\rightleftharpoons$ MgADP-phosphomyosin equilibrium\textsuperscript{8,9} which will be pH dependent and will probably have a bearing in the inhibitory binding of $\beta$-arrestin to the (MYL2)\textsuperscript{8,9}, i.e. it appears phosphorylated, and indicates a possible control mechanism coupled with MYL2 phosphorylation.

**What is excluded in FSLH**

As with the specific essential phosphorylations above the amplitude of tension has been shown by de tombe et al\textsuperscript{31} to be dependent on phosphorylation by PKA of both MyBP-C and cTn-I. Similar results were found with PKA phosphorylation of MyBP-C by Steltzer et al\textsuperscript{32}. However, all or part of their results could also arise through the above mechanism by direct phosphorylation of the inactive AT1R by the cyclic AMP stimulated PKA addition. Distinguishing one kinase activation in the presence of all is not a trivial matter, however on stretch no evidence for common PKA or C activation or deactivation is evident\textsuperscript{1,2,3,4}. The functions and role of MYL2 and its regulation in general muscle function are well reviewed\textsuperscript{30,33,34}, albeit various isoforms of the enzymes involved are present depending on type and muscle location.

**The future**

Clearly much work investigating the mechanism of length induced angiotensin receptor activation is needed. We also want to know if the specificity of the kinases mentioned here, MLCK and PKC-\(\beta\)II are altered by Ca\textsuperscript{2+}/calmodulin and autophosphorylation as is PKC-\(\beta\)II. The indications are that the small length induced increase of skeletal muscle contraction is down to MLCK alone and the more pronounced in cardiac muscle down to the addition of the presence and phosphorylation of cTn-I.

**Disclosures** NONE

**Grants** NONE
References,

1. Effect of protein kinase A on calcium sensitivity of force and its sarcomere length dependence in human cardiomyocytes. van der Velden, J., de Jong, J.W., Owen, V.J., Burton, P.B.J., Stienen, G.J.M., Cardiovascular Research; 46: 487–495 (2000)

2. Cardiac actions of protein kinase c isoforms. Steinberg, S. F., Physiology; 27(3): 130–139 (2012); doi:10.1152/physiol.00009.2012.

3. Effects of Protein Kinase A Phosphorylation on Signaling between Cardiac Troponin I and the N-Terminal Domain of Cardiac Troponin C. Chandra, M., Dong, W-J., Pan, B-S., Cheung, H. C. and Solaro R. J. Biochemistry; 36:13305-13311 (1997)

4. Effects of Protein Kinase C Dependent Phosphorylation and a Familial Hypertrophic Cardiomyopathy-Related Mutation of Cardiac Troponin I on Structural Transition of Troponin C and Myofilament Activation, Kobayashi, T., Dong, W-J., Burkart E. M., Cheung, H. C., and R. John Solaro R. J., Biochemistry; 43: 5996-6004 (2004)

5. The Mechanisms of the Frank-Starling Law and Familial Cardiomyopathy are Different. The Function of Myosin Binding Protein-C is Retained on Myocyte Length Increase and Force Generated is Kinase controlled. Smith, G. A., gas1000@cam.ac.uk, DOI: 10.20944/preprints201910.0068.v2, (2019-10-04) Smith, G. A., OAT, J. Integr. Cardiol.; 5: (2019) doi: 10.15761/JIC.1000278

6. Calcium, Actomyosin Kinetics, Myosin Binding Protein-C and Hypertrophic Cardiomyopathy. Smith, G. A., gas1000@cam.ac.uk, DOI: 10.20944/preprints201910.0067.v1 (2019-10-04) Smith, G. A., OAT, J. Integr. Cardiol.; 5: (2019) doi: 10.15761/JIC.1000277

7. Modulation of Ca\(^{2+}\) control of dog and rabbit cardiac myofibrils by Mg\(^{2+}\). Comparison with rabbit skeletal myofibrils. Solaro, R. J. and Shiner, J. S., Circ. Res.; 39: 8–14 (1976).

8. Time resolved measurements show that phosphate release is the rate limiting step on myofibrillar ATPases. Corinne Lionne, C., Brune, M., Martin R. Webb, M. R., Travers, F., Barman, T., FEBS Letters; 364: 59-62 (1995)

9. Transient state phosphate production in the hydrolysis of nucleoside triphosphates by myosin. Lynn, R. W. and Taylor, E. W., Biochemistry; 9 :2975–2983 (1970)
10. Calcium-binding properties of troponin-C in detergent skinned heart muscle fibers. Pan, B. S. and Solaro, R. J., J. Biol. Chem.; 262: 7839-49 (1987)

11. Ca$^{2+}$ binding to cardiac troponin-C in the myofilament lattice and its relation to myofibrillar ATPase activity. Morimoto, S. and Ohtsuki, I. Eur. J. Biochem.; 226: 597-602 (1994).

12. Myosin binding protein-C activates thin filaments and inhibits thick filaments in heart muscle cells. Kampourakis, T., Yan, Z., Gautel, M., Sun, Y-B, and Irving, M., PNAS ;111: 52, 18763–18768 (2014)

13. Alterations in Ca$^{2+}$ sensitive tension due to partial extraction of C-protein from rat skinned cardiac myocytes and rabbit skeletal muscle fibers. Hofmann, P. A., Hartzell, H.C., Moss R. L., J. Gen. Physiol.;97:1141–63 (1991)

14. Distinct contributions of the thin and thick filaments to length-dependent activation in heart muscle. Zhang, X., Kampourakis, T., Yan, Z., Sevrieva, I., Irving, M., SunY-B., eLife Sciences; 6: e24081 (2017)

15. Myofilament length dependent activation. de Tombe, P. P., Mateja, R. D., Tachampa, K., Mou, Y. A., Farman, G. P., Irving, T. C. J. Mol. Cell. Cardiol.; 48: 851–8 (2010)

16. The Cardiac Troponin C Isoform and the Length Dependence of Ca$^{2+}$ Sensitivity of Tension in Myocardium. Akella, A. B., Hong Su, Sonnenblick, E. H., Rao V. G. and Gulati J. J Mol Cell Cardiol 29, 381–389 (1997)

17. Cardiac Troponin I Threonine 144. Role in Myofilament Length–Dependent Activation, Tachampa, K., Wang, H., Farman, G. P., de Tombe, P. P., Circ. Res.;101:1081-1083 2007

18. PKC-βII sensitizes cardiac myofilaments to Ca$^{2+}$ by phosphorylating troponin I on threonine-144. Wang, H., Grant, J. E., Doede, C. M., Sadayappan, D., Robbins, J., Walker, J. W., J. Mol. Cell. Cardiol.; 41: 5, , 823-833 2006

19. Protein Kinase C-βII Specifically Binds to and Is Activated by F-actin. Blobe, G. C., Stribling, D. S., Fabbro, D., Stabel, S. and Hannun, Y. A., J. Biol. Chem.; 271, 26: 15823–15830 (1996)

20. β-Arrestin mediates the Frank–Starling mechanism of cardiac contractility. Abraham, D. M., Davis, R.T., Warren, C. M., Mao, L., Wolska, B. M., Solaro, R. J. and Rockman, H. A., PNAS; 113: 50: 14426–14431 (2016)

21. Purification of myosin light chain kinase from bovine cardiac muscle
Wolf, H. and Hofmann, F., Proc. Natl. Acad. Sci. USA; 77, 10: 5852-5855 (1980)

22, Purification and Characterization of Bovine Cardiac Calmodulin dependent Myosin Light Chain Kinase. Walsh, M.P., Vallet, B., Autric, F. and Demaille J. G., J Biol. Chem.; 254, 23: 12136-12144, (1979)

23, Site-specific phosphorylation of myosin binding protein-C coordinates thin and thick filament activation in cardiac muscle, Ponnam, S., Sevrieva, I., Sun, Y-B., Irving, M. and Kampourakis, T., PNAS; 116, 31:15485-15494 (2019)

24, The G protein-coupled receptor kinase (GRK) interactome: Role of GRKs in GPCR regulation and signaling. Ribas, C., Penela, P., Murga, C., Salcedo, A., García-Hoz, C., Jurado-Pueyo, M., Aymerich, I., Mayor Jr, F., Biochimica et Biophysica Acta (BBA) – Biomembranes 1768, 4, 913-922 (2007)

25, GPCR Signaling Regulation: The Role of GRKs and Arrestins. Gurevich, V. V. and Gurevich, E. V., Frontiers in Pharmacology; 10: Article 125 (2019)

26, Phosphodiesterase activation by photoexcited rhodopsin is quenched when rhodopsin is phosphorylated and binds the intrinsic 48-kDa protein of rod outer segments. Wilden U, Hall SW, Kühn H PNAS. 83 (5): 1174–8. (1986); doi:10.1073/pnas.83.5.1174

27, Rapid affinity purification of retinal arrestin (48 kDa protein) via its light-dependent binding to phosphorylated rhodopsin. Wilden, U., Wüst, E., Weyand, I., and Kühn, H. FEBS Lett. 207, 292–295 (1986)

28, Cardiac Myosin Light Chain Kinase, A New Player in the Regulation of Myosin Light Chain in the Heart. Ishikawa, Y. and Kurotani, R., Circ. Res.; 102: 516-518 (2008)

29, Acceleration of stretch activation in murine myocardium due to phosphorylation of myosin regulatory light chain. Stelzer, J. E., Patel, J. R., Moss, R. L. J. Gen. Physiol.; 128: 261–272 (2006)

30, Role of myosin light chain phosphatase in cardiac physiology and pathophysiology. Chang, A. N., Kamm, K. E., Stull, J. T., J. Mol. Cell. Cardiol.; 101 :35–43 (2016)

31, Cardiac myosin-binding protein C and troponin-I phosphorylation independently modulate myofilament length-dependent activation. Kumar, M., Govindan, S., Zhang, M., Khairallah, R. J., Martin, J. L., Sadayappan, S., de Tombe, P. P., J. Biol. Chem.; 290: 29241–29249 (2015).
32, Cardiac Myosin Binding Protein-C Phosphorylation Modulates Myofilament Length-Dependent Activation. Mamidi, R., Gresham, K. S., Verma, S., and Stelzer J. E., Frontiers in physiology; 7: Article 38 (2016)

33, Functions of myosin light chain-2 (MYL2) in cardiac muscle and disease. Sheikh, F., Lyon, R.C., Chen, J., Gene ;569: 14–20 (2015)

34, Cardiac Myosin Light Chain Kinase Is Necessary for Myosin Regulatory Light Chain Phosphorylation and Cardiac Performance in Vivo. Ding, P., Huang, J., Battiprolu, P. K., Joseph A. Hill, J. A., Kristine E. Kamm, K. E. and Stull, J. T., J. Biol. Chem.; 285, 52: 40819-40829 (2010)